Non-Small Cell Lung Cancer Market Size Worth USD 129.88 Billion by 2034 | CAGR: 14.3%

The non-small cell lung cancer market size is expected to reach USD 129.88 Billion by 2034, according to a new study by Polaris Market Research. The report “Non-Small Cell Lung Cancer Market Share, Size, Trends, Industry Analysis Report: By Type, By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, and Others), By Distribution Channel, and By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Non-small cell lung cancer (NSCLC) represents the majority of global lung cancer cases and is driving advances in precision oncology. Increasing use of biomarker testing, targeted therapies, and immunotherapies is reshaping treatment approaches, while innovations in liquid biopsy and mutation-specific drugs are enabling earlier diagnosis and better outcomes.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/non-small-cell-lung-cancer-market/request-for-sample

Market growth is primarily driven by the rising global incidence of NSCLC, increasing adoption of targeted and immune-based therapies and the growing availability of companion diagnostics that support personalized treatment plans.

Non-Small Cell Lung Cancer Market Report Highlights

• Based on type, the adenocarcinoma segment dominated the market share in 2024, driven by its high prevalence and strong response to targeted therapy options.
• In terms of treatment, the targeted therapy segment dominated the market in 2024, supported by the broad clinical use of EGFR, ALK, and KRAS inhibitors.
• Based on distribution channel, the hospital pharmacy segment dominated the market in 2024, due to centralized access to advanced oncology drugs and clinical oversight.
• North America accounted for the majority share in the global non-small cell lung cancer market in 2024, driven by early adoption of molecular diagnostics and regulatory support for novel therapies.
• Asia Pacific is projected to grow at the fastest CAGR during the forecast period, owing to rising cancer incidence, expanding healthcare access, and growing investment in oncology research.
• A few global key market players include Roche Holding AG, AstraZeneca PLC, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Eli Lilly And Company, Novartis AG, Johnson & Johnson, Amgen Inc., Beigene Ltd., Exelixis Inc., and Mirati Therapeutics Inc.

Polaris Market Research has segmented the market report on the basis of type, treatment, distribution channel, and region:

By Type Outlook (Revenue, USD Billion, 2020–2034)

• Squamous Cell Carcinoma
• Large Cell Carcinoma
• Adenocarcinoma
• Other Type

By Treatment Outlook (Revenue, USD Billion, 2020–2034)

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Others

By Distribution Channel Outlook (Revenue, USD Billion, 2020–2034)

• Hospital Pharmacy
• Drug Store and Retail Pharmacy
• Online Pharmacy

By Regional Outlook (Revenue, USD Billion, 2020–2034)

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America